Analysts at Mizuho increased their price target on shares of Covidien plc (NYSE: COV) from $61.00 to $64.00 in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the stock.
A number of other firms have also recently commented on COV. Analysts at Deutsche Bank (NYSE: DB) raised their price target on shares of Covidien plc from $59.00 to $62.00 in a research note to investors on Tuesday, May 1st. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray (NYSE: PJC) raised their price target on shares of Covidien plc from $60.00 to $64.00 in a research note to investors on Monday, April 30th. They now have an “overweight” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Covidien plc in a research note to investors on Monday, April 30th. They now have a $58.00 price target on the stock.
Covidien plc opened at 54.25 on Monday. Covidien plc has a 1-year low of $41.35 and a 1-year high of $57.65. The company has a market cap of $26.221 billion and a price-to-earnings ratio of 13.50.
Covidien plc last released its earnings data on Friday, April 27th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Analysts expect that Covidien plc will post $1.07 EPS next quarter.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.